Related references
Note: Only part of the references are listed.Therapeutic approaches for protecting bone health in patients with breast cancer
Diana Lueftner et al.
BREAST (2018)
The bone remodelling cycle
J. S. Kenkre et al.
ANNALS OF CLINICAL BIOCHEMISTRY (2018)
Osteomimicry: How the Seed Grows in the Soil
Nadia Rucci et al.
CALCIFIED TISSUE INTERNATIONAL (2018)
Bone-Targeted Therapies in Cancer-Induced Bone Disease
Sofia Sousa et al.
CALCIFIED TISSUE INTERNATIONAL (2018)
Bone targeted therapies in advanced breast cancer
Biskup Ewelina et al.
SWISS MEDICAL WEEKLY (2017)
Risks and Benefits of Bisphosphonate Therapies
Carlen Reyes et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2016)
Calcium-Sensing Receptor Promotes Breast Cancer by Stimulating Intracrine Actions of Parathyroid Hormone-Related Protein
Wonnam Kim et al.
CANCER RESEARCH (2016)
Physiological Bone Remodeling: Systemic Regulation and Growth Factor Involvement
Jawed A. Siddiqui et al.
PHYSIOLOGY (2016)
Sclerostin, an emerging therapeutic target for treating osteoporosis and osteoporotic fracture: A general review
Pui Kit Suen et al.
JOURNAL OF ORTHOPAEDIC TRANSLATION (2016)
Hypocalcaemia in patients with metastatic bone disease treated with denosumab
Jean-Jacques Body et al.
EUROPEAN JOURNAL OF CANCER (2015)
A Randomized, Double-Blind Phase 2 Clinical Trial of Blosozumab, a Sclerostin Antibody, in Postmenopausal Women with Low Bone Mineral Density
Robert R. Recker et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2015)
Tumour but not stromal expression of beta 3 integrin is essential, and is required early, for spontaneous dissemination of bone-metastatic breast cancer
Rachel Zoe Carter et al.
JOURNAL OF PATHOLOGY (2015)
Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials
R. Coleman et al.
LANCET (2015)
Reprint of: The Great Beauty of the osteoclast
Alfredo Cappariello et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2014)
RANK expression as a prognostic and predictive marker in breast cancer
Berit Maria Pfitzner et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
Integrating new discoveries into the vicious cycle paradigm of prostate to bone metastases
Leah M. Cook et al.
CANCER AND METASTASIS REVIEWS (2014)
Effect of aromatase inhibition on serum levels of sclerostin and dickkopf-1, bone turnover markers and bone mineral density in women with breast cancer
Ioannis Kyvernitakis et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2014)
Romosozumab in Postmenopausal Women with Low Bone Mineral Density
Michael R. McClung et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
被撤回的出版物: Osteolytic bone metastasis is hampered by impinging on the interplay among autophagy, anoikis and ossification (Retracted article. See vol. 13, 2022)
P. Maroni et al.
CELL DEATH & DISEASE (2014)
The anti-tumour effects of zoledronic acid
Jamal Zekri et al.
JOURNAL OF BONE ONCOLOGY (2014)
Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results
R. Coleman et al.
ANNALS OF ONCOLOGY (2013)
Podosomes in Adhesion, Migration, Mechanosensing and Matrix Remodeling
Hannah Schachtner et al.
CYTOSKELETON (2013)
Treatment of bone metastases before the onset of pain
Luis Costa et al.
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2013)
WNT signaling in bone homeostasis and disease: from human mutations to treatments
Roland Baron et al.
NATURE MEDICINE (2013)
The role of estrogen and androgen receptors in bone health and disease
Stavros C. Manolagas et al.
NATURE REVIEWS ENDOCRINOLOGY (2013)
Osteopetrosis: genetics, treatment and new insights into osteoclast function
Cristina Sobacchi et al.
NATURE REVIEWS ENDOCRINOLOGY (2013)
New regulation mechanisms of osteoclast differentiation
Tomoki Nakashima et al.
SKELETAL BIOLOGY AND MEDICINE II: BONE AND CARTILAGE HOMEOSTASIS AND BONE DISEASE (2011)
Biochemical and molecular mechanisms of action of bisphosphonates
Michael J. Rogers et al.
BONE (2011)
Metastatic breast cancer cells inhibit osteoblast differentiation through the Runx2/CBF beta-dependent expression of the Wnt antagonist, sclerostin
Daniel Mendoza-Villanueva et al.
BREAST CANCER RESEARCH (2011)
Pathogenesis of Osteoblastic Bone Metastases From Prostate Cancer
Toni Ibrahim et al.
CANCER (2010)
The Cathepsin K Inhibitor Odanacatib Suppresses Bone Resorption in Women With Breast Cancer and Established Bone Metastases: Results of a 4-Week, Double-Blind, Randomized, Controlled Trial
Anders Bonde Jensen et al.
CLINICAL BREAST CANCER (2010)
Bisphosphonates suppress insulin-like growth factor 1-induced angiogenesis via the HIF-1 alpha/VEGF signaling pathways in human breast cancer cells
Xudong Tang et al.
INTERNATIONAL JOURNAL OF CANCER (2010)
Oral Bisphosphonate Use and Breast Cancer Incidence in Postmenopausal Women
Rowan T. Chlebowski et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
SKI-606 (Bosutinib) Blocks Prostate Cancer Invasion, Growth, and Metastasis In vitro and In vivo through Regulation of Genes Involved in Cancer Growth and Skeletal Metastasis
Shafaat A. Rabbani et al.
MOLECULAR CANCER THERAPEUTICS (2010)
Effect of the Specific Src Family Kinase Inhibitor Saracatinib on Osteolytic Lesions Using the PC-3 Bone Model
Joy C. Yang et al.
MOLECULAR CANCER THERAPEUTICS (2010)
RANK ligand mediates progestin-induced mammary epithelial proliferation and carcinogenesis
Eva Gonzalez-Suarez et al.
NATURE (2010)
Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer
Daniel Schramek et al.
NATURE (2010)
Src family kinase/abl inhibitor dasatinib suppresses proliferation and enhances differentiation of osteoblasts
Y-C Lee et al.
ONCOGENE (2010)
Infantile Malignant, Autosomal Recessive Osteopetrosis: The Rich and The Poor
Anna Villa et al.
CALCIFIED TISSUE INTERNATIONAL (2009)
Future of anticathepsin K drugs: dual therapy for skeletal disease and atherosclerosis?
Izabela Podgorski
FUTURE MEDICINAL CHEMISTRY (2009)
Zoledronic acid induces caspase-dependent apoptosis in renal cancer cell lines
Anders Ullen et al.
SCANDINAVIAN JOURNAL OF UROLOGY AND NEPHROLOGY (2009)
The women's health initiative: Lessons learned
Ross L. Prentice et al.
ANNUAL REVIEW OF PUBLIC HEALTH (2008)
Osteoclast receptors and signaling
Andrea Del Fattore et al.
ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS (2008)
Osteoclast precursor interaction with bone matrix induces osteoclast formation directly by an interleukin-1-mediated autocrine mechanism
Zhenqiang Yao et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2008)
A cathepsin K inhibitor reduces breast cancer-induced osteolysis and skeletal tumor burden
Celine Le Gall et al.
CANCER RESEARCH (2007)
Effects of Vitaxin®, a novel therapeutic in trial for metastatic bone tumors, on osteoclast functions in vitro
Azza Gramoun et al.
JOURNAL OF CELLULAR BIOCHEMISTRY (2007)
Estrogen prevents bone loss via estrogen receptor α and induction of Fas ligand in osteoclasts
Takashi Nakamura et al.
CELL (2007)
Tumor ανβ3 integrin is a therapeutic target for breast cancer bone metastases
Yingshe Zhao et al.
CANCER RESEARCH (2007)
Dickkopf homolog 1 mediates endothelin-1-stimulated new bone formation
Gregory A. Clines et al.
MOLECULAR ENDOCRINOLOGY (2007)
Transcriptome analysis reveals an osteoblast-like phenotype for human osteotropic breast cancer cells
A. Bellahcene et al.
BREAST CANCER RESEARCH AND TREATMENT (2007)
v-ATPase V0 subunit d2-deficient mice exhibit impaired osteoclast fusion and increased bone formation
Seoung-Hoon Lee et al.
NATURE MEDICINE (2006)
Basic mechanisms responsible for osteolytic and osteoblastic bone metastases
Theresa A. Guise et al.
CLINICAL CANCER RESEARCH (2006)
Inhibition of protein kinase c-src reduces the incidence of breast cancer metastases and increases survival in mice: Implications for therapy
Nadia Rucci et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2006)
NFATc1 regulation of the human β3 integrin promoter in osteoclast differentiation
Tania N. Crotti et al.
GENE (2006)
A new endogenous ATP analog (ApppI) inhibits the mitochondrial adenine nucleotide translocase (ANT) and is responsible for the apoptosis induced by nitrogen-containing bisphosphonates
H Mönkkönen et al.
BRITISH JOURNAL OF PHARMACOLOGY (2006)
Recent advances in understanding the mechanism of action of bisphosphonates
Fraser P. Coxon et al.
CURRENT OPINION IN PHARMACOLOGY (2006)
Management of bone metastases in cancer: A review
G Selvaggi et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2005)
Autoamplification of NFATc1 expression determines its essential role in bone homeostasis
M Asagiri et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
Nuclear factor of activated T cells c1 induces osteoclast-associated receptor gene expression during tumor necrosis factor-related activation-induced cytokine-mediated osteoclastogenesis
K Kim et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2005)
DC-STAMP is essential for cell-cell fusion in osteoclasts and foreign body giant cells
M Yagi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
The role of matrix vesicles in growth plate development and biomineralization
HC Anderson et al.
FRONTIERS IN BIOSCIENCE-LANDMARK (2005)
Mechanisms of disease: Mechanisms of bone metastasis
GD Roodman
NEW ENGLAND JOURNAL OF MEDICINE (2004)
ADAM gene expression and regulation during human osteoclast formation
S Verrier et al.
BONE (2004)
Essential role of p38 mitogen-activated protein kinase in cathepsin K gene expression during osteoclastogenesis through association of NFATc1 and PU.1
M Matsumoto et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2004)
Altered fracture repair in the absence of MMP9
C Colnot et al.
DEVELOPMENT (2003)
Intracellular membrane trafficking in bone resorbing osteoclasts
M Mulari et al.
MICROSCOPY RESEARCH AND TECHNIQUE (2003)
Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial - The zoledronic acid lung cancer and other solid tumors study group
LS Rosen et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Comparison between solitary and multiple skeletal metastatic lesions of breast cancer patients
M Koizumi et al.
ANNALS OF ONCOLOGY (2003)
IL-3 acts directly on osteoclast precursors and irreversibly inhibits receptor activator of NF-κB ligand-induced osteoclast differentiation by diverting the cells to macrophage lineage
SM Khapli et al.
JOURNAL OF IMMUNOLOGY (2003)
Mechanisms of tumor metastasis to the bone: Challenges and opportunities
AH Reddi et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2003)
Interleukin-6 and interleukin-11 support human osteoclast formation by a RANKL-independent mechanism
O Kudo et al.
BONE (2003)
Induction and activation of the transcription factor NFATc1 (NFAT2) integrate RANKL signaling in terminal differentiation of osteoclasts
H Takayanagi et al.
DEVELOPMENTAL CELL (2002)
IL-6, leukemia inhibitory factor, and oncostatin M stimulate bone resorption and regulate the expression of receptor activator of NF-κB ligand, osteoprotegerin, and receptor activator of NF-κB in mouse calvariae
P Palmqvist et al.
JOURNAL OF IMMUNOLOGY (2002)
The bone lining cell: Its role in cleaning Howship's lacunae and initiating bone formation
V Everts et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2002)
Osteoclast-stimulating factor interacts with the spinal muscular atrophy gene product to stimulate osteoclast formation
N Kurihara et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2001)
Cancellous bone remodeling occurs in specialized compartments lined by cells expressing osteoblastic markers
EM Hauge et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2001)
Metastatic bone disease: clinical features, pathophysiology and treatment strategies
RE Coleman
CANCER TREATMENT REVIEWS (2001)
IL-12 alone and in synergy with IL-18 inhibits osteoclast formation in vitro
NJ Horwood et al.
JOURNAL OF IMMUNOLOGY (2001)
IL-4 inhibits osteoclast formation through a direct action on osteoclast precursors via peroxisome proliferator-activated receptor γ1
AC Bendixen et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2001)
TNF-α induces osteoclastogenesis by direct stimulation of macrophages exposed to permissive levels of RANK ligand
J Lam et al.
JOURNAL OF CLINICAL INVESTIGATION (2000)
Decreased c-Src expression enhances osteoblast differentiation and bone formation
M Marzia et al.
JOURNAL OF CELL BIOLOGY (2000)
Osteoclasts and giant cells: macrophage-macrophage fusion mechanism
A Vignery
INTERNATIONAL JOURNAL OF EXPERIMENTAL PATHOLOGY (2000)
RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism
J Li et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2000)
Activin A is an essential cofactor for osteoclast induction
K Fuller et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2000)
Tumor necrosis factor α stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction
K Kobayashi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)
Share Paper
